Clinical

Articles

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

Erdafitinib/Cetrelimab Combination Shows Strong Efficacy for Metastatic Urothelial Carcinoma

The FDA has approved nivolumab for patients with high-risk urothelial carcinoma regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status. 


FDA Approves Adjuvant Nivolumab for the Treatment of Patients With High-Risk Urothelial Carcinoma

Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with those who received placebo.  

Adjuvant Nivolumab Demonstrates Improved Disease-Free Survival Over Placebo in Muscle Invasive Urothelial Carcinoma

Novel eganelisib shows survival-extending potential in patients with triple-negative breast and bladder cancers.  

Eganelisib Combination Therapies Demonstrate Promising Survival Benefit in Advanced Urothelial Carcinoma and TNBC

Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.

Robert A. Figlin, MD, on the Potential Importance of Adjuvant IO in Bladder Cancer

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.

Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook

Videos

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer. 

Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer

As a bladder-sparing treatment strategy, transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise for patients with muscle-invasive bladder cancer.

TURBT With Nivolumab and Chemo Promising Bladder-Sparing Strategy in MIBC

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to talk about data from a phase 2 trial examining the use of neoadjuvant nivolumab plus gemcitabine/cisplatin prior to bladder-sparing surgery.

Matthew D. Galsky, MD, Discussed Multidisciplinary Care for Treating MIBC With TURBT and Nivolumab Combo

Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.


Bladder Cancer | Topics